Publications by authors named "Renaud Capdeville"

Claim this Profile
P
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Andrew D J Pearson, C Michel Zwaan, E Anders Kolb, Dominik Karres, Julie Guillot, Renaud Capdeville

Eur J Cancer· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
Andrew D J Pearson, Claudia Rossig, Giovanni Lesa, Scott J Diede, Susan Weiner, Renaud Capdeville

Eur J Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
Richard M Stone, Paul W Manley, Richard A Larson, Renaud Capdeville

Blood Adv· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of mechanism of action biology-driven early drug development for children with cancer.
Andrew D J Pearson, Ralf Herold, Raphaël Rousseau, Chris Copland, Brigid Bradley-Garelik, Renaud Capdeville

Eur J Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.
Marina Savelieva, Margaret M Woo, Horst Schran, Song Mu, Jerry Nedelman, Renaud Capdeville

Eur J Clin Pharmacol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.
Birgit Geoerger, Bruce Morland, Anna Ndiaye, Francois Doz, Gabriel Kalifa, Renaud Capdeville

Eur J Cancer· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer.
Herlinde Dumez, Helen Gall, Renaud Capdeville, Catherine Dutreix, Allan T van Oosterom

Anticancer Drugs· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, Patricia L Dahia, Yanfeng Wang, Renaud Capdeville

Clin Cancer Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.
Martin A Champagne, Renaud Capdeville, Mark Krailo, Wenchun Qu, Bin Peng

Blood· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
Catherine Dutreix, Bin Peng, Guenther Mehring, Michael Hayes, Renaud Capdeville

Cancer Chemother Pharmacol· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules.
Zariana Nikolova, Bin Peng, Martine Hubert, Michael Sieberling, Urs Keller, Renaud Capdeville

Cancer Chemother Pharmacol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).
Marlene A Dressman, Rachel Malinowski, Lee Anne McLean, Insa Gathmann, Renaud Capdeville

Clin Cancer Res· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Bin Peng, Michael Hayes, Debra Resta, Amy Racine-Poon, Brian J Druker, Renaud Capdeville

J Clin Oncol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Ann E Bolton, Bin Peng, Martine Hubert, Axel Krebs-Brown, Renaud Capdeville

Cancer Chemother Pharmacol· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.
Bin Peng, Catherine Dutreix, Gunther Mehring, Michael J Hayes, Monique Ben-Am, Renaud Capdeville

J Clin Pharmacol· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study.
Miklos Pless, Karim Belhadj, Hans D Menssen, Wolfgang Kern, Bertrand Coiffier, Renaud Capdeville

Clin Cancer Res· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Lee Anne McLean, Insa Gathmann, Renaud Capdeville, Mihael H Polymeropoulos, Marlene Dressman

Clin Cancer Res· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib: a targeted clinical drug development.
Renaud Capdeville, Sandra Silberman

Semin Hematol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Stephen G O'Brien, François Guilhot, Richard A Larson, Insa Gathmann, Michele Baccarani, Renaud Capdeville

N Engl J Med· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.
Catherine J Wu, Donna Neuberg, Antoinette Chillemi, Stephen McLaughlin, Ephraim P Hochberg, Renaud Capdeville

Leuk Lymphoma· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.
Michael E O'Dwyer, Michael J Mauro, Gwen Kurilik, Motomi Mori, Suzanne Balleisen, Renaud Capdeville

Blood· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Oliver G Ottmann, Brian J Druker, Charles L Sawyers, John M Goldman, Jose Reiffers, Renaud Capdeville

Blood· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib: the first 3 years.
Renaud Capdeville, Sandra Silberman, Sasa Dimitrijevic

Eur J Cancer· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Charles D Blanke, Annick D Van den Abbeele, Burton Eisenberg, Renaud Capdeville

N Engl J Med· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.
Renaud Capdeville, Elisabeth Buchdunger, Juerg Zimmermann, Alex Matter

Nat Rev Drug Discov· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis